

ORIGINAL ARTICLE

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

E.M. O'Reilly,¹ Z.A. Wainberg,² A.E. Hendifar,³ M.J. Borad,⁴ F. Pietrantonio,⁵ S. Pant,⁶ P. Hammel,⁷ C. Cremolini,⁸ G.A. Manji,⁹ P.E. Oberstein,¹⁰ I. Garrido-Laguna,¹¹ C. Springfield,¹² N.S. Azad,¹³ M. Ueno,¹⁴ S.Y. Chui,¹⁵ Y. Zhang,¹⁵ H. Patel,¹⁵ Y. Lee,¹⁵ Z. Salman,¹⁵ and B.M. Wolpin,¹⁶ for the RASolute 302 Trial Investigators*

ABSTRACT

BACKGROUND

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with oncogenic RAS mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS.

METHODS

In this phase 3, international, open-label, randomized trial, we randomly assigned patients with previously treated mPDAC to receive daraxonrasib or chemotherapy of the investigator's choice. The dual primary end points were overall survival and progression-free survival in the subpopulation of patients with RAS G12 mutations (the RAS G12 population). Key secondary end points included overall survival and progression-free survival in the overall population (which included patients with RAS G12, G13, or Q61 mutations or with no RAS mutation identified) and objective response and patient-reported quality of life in the RAS G12 and overall populations. Safety was also assessed.

RESULTS

A total of 500 patients, including 91.8% with RAS G12 mutations, were randomly assigned to receive daraxonrasib (248 patients) or chemotherapy (252 patients). The median overall survival in the RAS G12 population was 13.2 months with daraxonrasib and 6.6 months with chemotherapy, and the median overall survival in the overall population was 13.2 months and 6.7 months, respectively; the hazard ratio was 0.40 in both populations ($P < 0.001$). The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively ($P < 0.001$ for both comparisons). Adverse events that occurred after the start of treatment were reported in all the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group; the incidence of adverse events of grade 3 or higher was 61.8% and 69.6%, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group.

CONCLUSIONS

Among patients with previously treated mPDAC, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. (Funded by Revolution Medicines; RASolute 302 ClinicalTrials.gov number, NCT06625320.)

The authors' full names, academic degrees, and affiliations are listed at the end of the article. Eileen M. O'Reilly can be contacted at oreillye@mskcc.org or at Memorial Sloan Kettering Cancer Center, 160 E. 53rd St., New York, NY 10022. Zev A. Wainberg can be contacted at zwainberg@mednet.ucla.edu or at Jonsson Comprehensive Cancer Center, University of California, 2020 Santa Monica Blvd., Ste. 600, Santa Monica, CA 90404. Brian M. Wolpin can be contacted at brian_wolpin@dfci.harvard.edu or at Hale Family Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215.

*A list of the investigators in the RASolute 302 trial is provided in the Supplementary Appendix, available at NEJM.org.

Eileen M. O'Reilly, Zev A. Wainberg, and Brian M. Wolpin contributed equally to this article.

This article was published on May 31, 2026, at NEJM.org.

DOI: 10.1056/NEJMoa2605555

Copyright © 2026 Massachusetts Medical Society.

METHODS

TRIAL DESIGN AND OVERSIGHT

The RASolute 302 trial is a phase 3, international, open-label, randomized trial. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the institutional review board or ethics committee at each participating site. All the patients provided written informed consent. An independent data monitoring committee oversaw safety for the trial.

The trial protocol (available with the full text of this article at NEJM.org) was developed by the sponsor (Revolution Medicines) in collaboration with trial investigators. The statistical analyses were performed and validated by the sponsor according to the prespecified statistical analysis plan. All the authors had access to the data, participated in the interpretation of the data, and contributed to the preparation of the manuscript. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol. Medical writing assistance with the submitted manuscript was funded by the sponsor.

PATIENTS

Eligible patients were at least 18 years of age, had histologically or cytologically confirmed mPDAC, and had previous disease progression after the receipt of one previous line of a fluoropyrimidine- or gemcitabine-based therapy for metastatic disease or after the receipt of neoadjuvant or adjuvant therapy if metastatic disease was diagnosed less than 6 months after the last dose of such therapy. Patients were required to have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater disability); and adequate organ function.²⁷ Additional eligibility criteria included a tumor with a documented RAS mutational status, defined as either a nonsynonymous mutation in KRAS, NRAS, or HRAS at codon 12, 13, or 61 (G12, G13, or Q61), or no tumor with a RAS mutation identified. Patients who did not have a tumor harboring an identified RAS mutation but who had another actionable driver alteration were required to have received approved targeted therapy. Key

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) is one of the most lethal cancers, with most patients presenting with advanced disease at the time of diagnosis.¹⁻³ Among patients with metastatic PDAC (mPDAC), the median overall survival is less than 1 year.^{2,5} No single standard treatment has been established for the population of patients with previously treated mPDAC.⁶ Although a small number of targeted therapies are available, their use is limited to rare molecular subgroups, and most patients receive cytotoxic chemotherapy.⁷ These chemotherapy options typically involve fluoropyrimidine- or gemcitabine-based regimens, but patient outcomes are poor, with a low incidence of response, a median progression-free survival of 3 to 4 months, a median overall survival of 6 to 7 months, and substantial toxic effects.^{6,8-14}

Oncogenic mutations of the gene family that encodes rat sarcoma virus (RAS) are primary drivers of PDAC that are present in more than 90% of tumors, and most of these mutations (>80%) involve substitutions at KRAS codon 12.¹⁵⁻¹⁸ These alterations result in constitutive activation of RAS with accumulation of the guanosine triphosphate (GTP)-bound state of RAS, known as RAS(ON), which drives aberrant signaling.^{18,19} Tumors lacking RAS mutations and other clinically actionable mutations can also be dependent on RAS signaling through genomic amplification or alterations in upstream or downstream components of the RAS-mitogen-activated protein kinase (MAPK) pathway.²⁰⁻²²

Daraxonrasib is an oral, potent RAS(ON) multiselective, tri-complex inhibitor that binds to cyclophilin A intracellularly to form a binary complex that engages RAS(ON) and suppresses downstream signaling.^{19,23-25} Daraxonrasib is selective for the active state of both mutant and wild-type RAS across KRAS, NRAS, and HRAS, including variants with mutations at glycine 12 (G12), glycine 13 (G13), and glutamine 61 (Q61).^{23,24}

In a phase 1-2 trial, daraxonrasib showed clinical activity with mainly low-grade adverse events, including rash and gastrointestinal side effects, in patients with advanced PDAC.²⁶ These findings led to the phase 3 RASolute 302 trial, in which daraxonrasib is being compared with the investigator's choice of standard chemotherapy in patients with previously treated mPDAC. Here, we report the primary results of the RASolute 302 trial.

exclusion criteria were known central nervous system metastases and previous RAS-targeted therapy. Full eligibility criteria are provided in the protocol.

RANDOMIZATION AND TREATMENT

Patients were randomly assigned in a 1:1 ratio to receive daraxonrasib at a dose of 300 mg orally once daily or the investigator's choice of chemotherapy (gemcitabine plus nab-paclitaxel, modified FOLFIRINOX [fluorouracil, irinotecan, leucovorin, and oxaliplatin], FOLFOX [fluorouracil, leucovorin, and oxaliplatin], or liposomal irinotecan plus fluorouracil and leucovorin). Chemotherapy was administered according to the local prescribing practice.

Randomization was performed with the use of an interactive response technology system and was stratified according to ECOG performance-status score (0 or 1), presence or absence of metastatic disease at the time of initial diagnosis, presence or absence of liver metastases at baseline, and RAS mutational status (RAS G12D or G12V mutation, other RAS G12 mutation, or RAS G13 or Q61 mutation or no tumor with a RAS mutation identified). Treatment continued until disease progression or unacceptable toxic effects had occurred or consent was withdrawn, whichever happened first. Crossover to the other treatment group was not permitted.

END POINTS

The dual primary end points were overall survival and progression-free survival as assessed by blinded independent central review according to RECIST, version 1.1, in the subpopulation of patients with RAS G12 mutations (the RAS G12 population). Key secondary end points included overall survival and progression-free survival as assessed by blinded independent central review in the overall population (defined as the subpopulation of patients whose tumors harbored RAS mutations at G12, G13, or Q61 or patients in whom no RAS mutation was identified), objective response in the RAS G12 and overall populations, and patient-reported quality-of-life end points in the RAS G12 and overall populations. The specific patient-reported end points were the time to deterioration as assessed on the basis of pain (defined as the time to an increase of ≥ 10 points from baseline in the score on the European Organization for Research and Treatment of Cancer

Quality of Life Questionnaire pancreatic cancer pain scale [EORTC QLQ-PAN26] or death, whichever occurred first) and the time to deterioration as assessed on the basis of global health status—quality of life (defined as the time to a decrease of ≥ 10 points from baseline in the score on the EORTC Core Quality of Life Questionnaire—Core 30 [EORTC QLQ-C30] global health status—quality-of-life scale or death, whichever occurred first).

Additional secondary end points included time to response and safety. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.²⁸ The safety population included all the patients who received at least one dose of the trial treatment.

STATISTICAL ANALYSIS

The Kaplan–Meier method was used to estimate overall survival and progression-free survival. Differences between the treatment groups were assessed with the stratified log-rank test. Hazard ratios and corresponding 95% confidence intervals were calculated with the stratified Cox model with Efron's method of handling ties. The same stratification factors that were used for randomization were applied to the stratified log-rank test and Cox model.

The overall type I error rate was controlled at a two-sided alpha level of 5% with the use of a graphical multiple testing procedure.²⁹ The alpha was initially split between the dual primary end points in the RAS G12 population, whereby 0.2% was allocated to progression-free survival (blinded independent central review) and 4.8% to overall survival. Progression-free survival and overall survival were tested sequentially in the RAS G12 population and then in the overall population. If significance for the treatment effect was shown for both progression-free survival and overall survival in both populations, key secondary end points including objective response and patient-reported end points were tested sequentially in the RAS G12 population and then in the overall population. Additional analyses that were not included in the prespecified multiplicity-controlled testing procedure were descriptive in nature.

For the analysis of overall survival in the RAS G12 population, 314 deaths would need to occur to provide the trial with approximately 84% power at a two-sided alpha level of 4.8%, under the assumption of a hazard ratio of 0.70 (darax-

onrasib vs. chemotherapy). For the analysis of progression-free survival in the RAS G12 population, 235 events would need to occur to provide the trial with approximately 95% power at a two-sided alpha level of 0.2%, under the assumption of a hazard ratio of 0.54.

Two interim analyses of overall survival were planned to be performed before the final analysis in the RAS G12 population. The first interim analysis, which was also the final analysis for progression-free survival, was planned to be performed after the completion of enrollment and after at least 166 deaths had occurred in the RAS G12 population. All the data reported here are based on the first interim analysis. The full statistical analysis plan, including the analysis methods for the key secondary end points, is provided with the protocol.

RESULTS

PATIENTS

Between October 16, 2024, and November 7, 2025, a total of 500 patients at 59 sites in six countries were randomly assigned to receive daraxonrasib (248 patients) or chemotherapy (252 patients) (Fig. 1). A total of 459 patients (91.8%) who were enrolled in the trial had RAS G12 mutations.

The demographic and baseline disease characteristics of the patients were generally balanced across the treatment groups (Table 1). In the overall population, both treatment groups included patients with no RAS mutation identified: 9 patients in the daraxonrasib group and 7 patients in the chemotherapy group. A table showing the representativeness of the trial population as compared with the disease distribution is provided in Table S1 in the Supplementary Appendix, available at NEJM.org.

A total of 241 of the randomly assigned patients in the daraxonrasib group (97.2%) and 214 of those in the chemotherapy group (84.9%) received at least one dose of the trial treatment. In the chemotherapy group, in which patients received the investigator's choice of chemotherapy, the regimens that were administered were gemcitabine plus nab-paclitaxel (in 56.5% of the patients), liposomal irinotecan plus fluorouracil and leucovorin (in 32.7%), modified FOLFIRINOX (in 5.6%), and FOLFOX (in 5.1%).

At the time of data cutoff (February 10, 2026),

the median duration of follow-up was 8.5 months (range, 3.2 to 15.9). The median duration of treatment in the daraxonrasib group was 6.2 months (range, <0.1 to 14.1), with a median dose intensity of 93.1% (range, 32.9 to 100.0). In the chemotherapy group, the median duration of treatment was 1.9 months (range, <0.1 to 12.5) with gemcitabine plus nab-paclitaxel, 3.1 months (range, 0.1 to 11.2) with liposomal irinotecan plus fluorouracil and leucovorin, 3.2 months (range, 0.1 to 12.9) with modified FOLFIRINOX, and 1.5 months (range, 0.1 to 7.0) with FOLFOX. The median dose intensity across the chemotherapy regimens ranged from 65 to 95%.


EFFICACY

Overall Survival

In the RAS G12 population (459 patients), the median overall survival was 13.2 months (95% confidence interval [CI], 10.0 to not reached) in the daraxonrasib group as compared with 6.6 months (95% CI, 5.4 to 8.2) in the chemotherapy group (hazard ratio for death, 0.40; 95% CI, 0.30 to 0.54; $P<0.001$) (Fig. 2A). In the overall population (500 patients), the median overall survival was 13.2 months (95% CI, 10.0 to not reached) in the daraxonrasib group as compared with 6.7 months (95% CI, 5.8 to 8.0) in the chemotherapy group (hazard ratio for death, 0.40; 95% CI, 0.30 to 0.53; $P<0.001$) (Fig. 2B). At 9 months, overall survival among the patients without RAS G12 mutations (those with RAS G13 or Q61 mutations or no RAS mutation) was 55.4% (95% CI, 25.6 to 77.4) in the daraxonrasib group and 31.6% (95% CI, 10.4 to 55.7) in the chemotherapy group. Among the patients without RAS G12 mutations (41 patients), 7 of 20 patients have died in the daraxonrasib group as compared with 14 of 21 patients in the chemotherapy group (hazard ratio, 0.37; 95% CI, 0.15 to 0.93). The observed overall survival benefit of daraxonrasib over chemotherapy appeared to be generally consistent across prespecified subgroups, including RAS mutational status (Fig. S1).

Progression-free Survival

In the RAS G12 population, the median progression-free survival, assessed by blinded independent central review, was 7.3 months (95% CI, 6.3 to 8.1) with daraxonrasib as compared with 3.5 months (95% CI, 2.9 to 3.8) with chemotherapy (hazard



ratio for disease progression or death, 0.45; 95% CI, 0.34 to 0.59; $P < 0.001$) (Fig. 3A). In the overall population, the median progression-free survival was 7.2 months (95% CI, 5.7 to 7.5) and 3.6 months (95% CI, 2.9 to 4.2) in the daraxonrasib and chemotherapy groups, respectively (hazard ratio for disease progression or death, 0.49; 95% CI, 0.38 to 0.64; $P < 0.001$) (Fig. 3B). Among the 41 patients without RAS G12 mutations, disease progression or death occurred in 15 of 20 patients in the daraxonrasib group as compared with 9 of

21 patients in the chemotherapy group (hazard ratio, 1.38; 95% CI, 0.60 to 3.17). There appeared to be a progression-free survival benefit of daraxonrasib over chemotherapy in most of the pre-specified subgroups (Fig. S2).

Objective Response

In the RAS G12 population, the objective response was 33.2% (95% CI, 27.0 to 39.9) with daraxonrasib as compared with 11.8% (95% CI, 7.8 to 16.8) with chemotherapy (Table S2). In the overall popu-

Table 1. Demographic and Baseline Disease Characteristics (RAS G12 Population and Overall Population).*

Characteristic	RAS G12 Population		Overall Population	
	Daraxonrasib (N=228)	Chemotherapy (N=231)	Daraxonrasib (N=248)	Chemotherapy (N=252)
Median age (range) — yr	66 (30–88)	65 (36–86)	66 (30–88)	65 (36–86)
Age ≥65 yr — no. (%)	123 (53.9)	121 (52.4)	134 (54.0)	131 (52.0)
Sex — no. (%)				
Female	111 (48.7)	100 (43.3)	117 (47.2)	108 (42.9)
Male	117 (51.3)	131 (56.7)	131 (52.8)	144 (57.1)
Race or ethnic group — no. (%)†				
American Indian or Alaska Native	0	1 (0.4)	0	1 (0.4)
Asian	29 (12.7)	25 (10.8)	29 (11.7)	28 (11.1)
Black	6 (2.6)	14 (6.1)	7 (2.8)	15 (6.0)
White	155 (68.0)	152 (65.8)‡	172 (69.4)	167 (66.3)‡
Other	5 (2.2)	5 (2.2)	5 (2.0)	6 (2.4)
Race or ethnic group not obtained	30 (13.2)	27 (11.7)	32 (12.9)	28 (11.1)
Unknown	3 (1.3)	7 (3.0)	3 (1.2)	7 (2.8)
Geographic region — no. (%)				
North America	132 (57.9)	143 (61.9)	145 (58.5)	158 (62.7)
Europe	80 (35.1)	70 (30.3)	87 (35.1)	74 (29.4)
Asia Pacific	16 (7.0)	18 (7.8)	16 (6.5)	20 (7.9)
ECOG performance-status score — no. (%)§				
0	120 (52.6)	109 (47.2)	129 (52.0)	118 (46.8)
1¶	108 (47.4)	122 (52.8)	119 (48.0)	134 (53.2)
Metastatic disease at initial diagnosis — no. (%)	139 (61.0)	140 (60.6)	154 (62.1)	154 (61.1)
No. of previous systemic therapies for metastatic disease — no. (%)				
0	41 (18.0)	33 (14.3)	42 (16.9)	34 (13.5)
1	187 (82.0)	198 (85.7)	206 (83.1)	218 (86.5)
Select previous chemotherapy regimens for metastatic disease — no. (%)				
Modified FOLFIRINOX or FOLFIRINOX	91 (39.9)	98 (42.4)	98 (39.5)	105 (41.7)
Gemcitabine plus nab-paclitaxel	85 (37.3)	82 (35.5)	94 (37.9)	94 (37.3)
NALIRIFOX	4 (1.8)	7 (3.0)	4 (1.6)	8 (3.2)
Liposomal irinotecan plus fluorouracil and leucovorin	1 (0.4)	3 (1.3)	2 (0.8)	3 (1.2)
FOLFOX	2 (0.9)	3 (1.3)	2 (0.8)	3 (1.2)
Previous pancreatectomy — no. (%)	80 (35.1)	86 (37.2)	83 (33.5)	92 (36.5)
Previous Whipple procedure	54 (23.7)	52 (22.5)	57 (23.0)	56 (22.2)
Sites of metastases — no. (%)				
Liver	161 (70.6)	162 (70.1)	174 (70.2)	176 (69.8)
Lung	89 (39.0)	82 (35.5)	96 (38.7)	88 (34.9)
Peritoneum	72 (31.6)	77 (33.3)	76 (30.6)	83 (32.9)
Blood level of CA 19-9 ≥40 U/ml — no. (%)	194 (85.1)	179 (77.5)	211 (85.1)	195 (77.4)

Table 1. (Continued.)

Characteristic	RAS G12 Population		Overall Population	
	Daraxonrasib (N=228)	Chemotherapy (N=231)	Daraxonrasib (N=248)	Chemotherapy (N=252)
RAS mutational status — no. (%)				
RAS G12D or G12V mutation	197 (86.4)	197 (85.3)	197 (79.4)	197 (78.2)
Other RAS G12 mutation	31 (13.6)	34 (14.7)	31 (12.5)	34 (13.5)
RAS G13 or Q61 mutation, or no RAS mutation identified	0	0	20 (8.1)**	21 (8.3)**

* The RAS G12 population comprised patients with RAS G12 mutations. The overall population comprised patients whose tumors harbored RAS mutations at G12, G13, or Q61 or patients in whom no RAS mutation was identified. Percentages may not total 100 because of rounding. FOLFIRINOX denotes fluorouracil, irinotecan, leucovorin, and oxaliplatin; FOLFOX fluorouracil, leucovorin, and oxaliplatin; and NALIRIFOX liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin.

† Race and ethnic group were reported by the patients.

‡ The number of patients includes 1 patient whose race was documented as White and Asian.

§ Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.

¶ Three patients (2 randomly assigned to the daraxonrasib group and 1 to the chemotherapy group) had an ECOG performance-status score higher than 1 at baseline; therefore, these patients no longer met the trial eligibility criteria and received no doses of the trial treatment.

|| This category includes 42 patients in the daraxonrasib group and 33 patients in chemotherapy group who received previous treatment in the context of neoadjuvant or adjuvant disease but progressed to metastatic disease less than 6 months after the last dose of such therapy. One patient with a diagnosis of metastatic disease had a line of therapy that was incorrectly categorized as treatment for locally advanced disease.

** Nine patients in the daraxonrasib group and 7 patients in the chemotherapy group had no identified RAS mutation.

lation, the response was 31.6% (95% CI, 25.8 to 38.0) with daraxonrasib as compared with 11.2% (95% CI, 7.5 to 15.9) with chemotherapy. The median time to response across the RAS G12 and overall populations was 1.9 months (range, 1.3 to 7.4) in the daraxonrasib group and 1.9 months (range, 1.7 to 7.3) in the chemotherapy group.

Patient-Reported End Points


The time to deterioration as assessed on the basis of pain and global health status—quality of life was significantly longer with daraxonrasib than with chemotherapy in both the RAS G12 population and the overall population. The median time to deterioration, which included death as an event, for the symptom of pain was 9.0 months with daraxonrasib and 3.7 months with chemotherapy in the RAS G12 population and was 9.2 months with daraxonrasib and 3.8 months with chemotherapy in the overall population (hazard ratio, 0.51; 95% CI, 0.37 to 0.71; $P<0.001$, for both comparisons). For global health status—quality of life, the corresponding medians were 5.6 months and 2.4 months in the RAS G12 population (hazard ratio, 0.60; 95% CI, 0.45 to 0.80; $P<0.001$) and 5.7 months and 2.6 months in the overall popu-

lation (hazard ratio, 0.60; 95% CI, 0.46 to 0.79; $P<0.001$) (Fig. S3).

SAFETY

Adverse events of any grade, and regardless of attribution, that occurred after the start of treatment were reported in 100% of the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group (Table 2). The most common events in the daraxonrasib group were rash (in 86.3% of the patients), diarrhea (in 67.2%), stomatitis (in 54.8%), nausea (in 52.3%), vomiting (in 42.3%), fatigue (in 33.6%), and anemia (in 29.9%). In the chemotherapy group, the most commonly reported events were fatigue (in 45.3% of the patients), anemia (in 44.9%), nausea (in 42.1%), diarrhea (in 41.6%), neutropenia (in 39.3%), thrombocytopenia (in 33.6%), decreased appetite (in 27.1%), and peripheral neuropathy (in 26.6%). Adverse events of grade 3 or higher that occurred after the start of treatment were reported in 61.8% of the patients in the daraxonrasib group and in 69.6% of those in the chemotherapy group.

Adverse events that were considered by the investigators to be related to the trial treatment oc-


A Overall Survival in the RAS G12 Population

	No. of Patients	No. of Events (%)	Median Overall Survival (95% CI) mo
Daraxonrasib	228	72 (32)	13.2 (10.0–NR)
Chemotherapy	231	127 (55)	6.6 (5.4–8.2)

Hazard ratio for death, 0.40 (95% CI, 0.30–0.54)
P<0.001

No. at Risk

Daraxonrasib	228	220	217	206	191	171	150	112	81	57	33	23	11	7	4	1	0
Chemotherapy	231	214	197	175	144	113	96	69	49	32	19	10	5	2	0		

B Overall Survival in the Overall Population

	No. of Patients	No. of Events (%)	Median Overall Survival (95% CI) mo
Daraxonrasib	248	79 (32)	13.2 (10.0–NR)
Chemotherapy	252	141 (56)	6.7 (5.8–8.0)

Hazard ratio for death, 0.40 (95% CI, 0.30–0.53)
P<0.001

No. at Risk

Daraxonrasib	248	240	237	225	208	188	165	125	90	62	37	24	11	7	4	1	0
Chemotherapy	252	235	217	193	161	126	108	78	53	35	21	10	5	2	0		

Figure 2. Overall Survival.


The RAS G12 population comprised patients with RAS G12 mutations. The overall population comprised patients whose tumors harbored RAS mutations at G12, G13, or Q61 or patients in whom no RAS mutation was identified. Hazard ratios and 95% confidence intervals were based on the stratified Cox model with Efron's method of handling ties. P values were calculated with the stratified log-rank test. NR denotes not reached.

occurred in 97.9% of the patients in the daraxonrasib group and in 93.5% of those in the chemotherapy group. Treatment-related adverse events of grade 3 or higher were less common with daraxonrasib than with chemotherapy (in 43.6% of the patients vs. 57.5%), as were serious treatment-related adverse events (in 10.8% vs. 18.7%). The incidence of treatment-related adverse events that led to dose reduction was also lower in the daraxonrasib group than in the chemotherapy group (in 36.1% of the patients vs. 57.5%).

The most commonly reported treatment-related adverse events in the daraxonrasib group were rash (in 85.5% of the patients), diarrhea (in 58.1%),

stomatitis (in 53.1%), nausea (in 46.5%), and vomiting (in 36.9%). In the chemotherapy group, the most common such events were fatigue (in 44.4% of the patients), anemia (in 39.7%), nausea (in 39.3%), neutropenia (in 38.3%), diarrhea (in 37.9%), thrombocytopenia (in 33.2%), and peripheral neuropathy (in 25.2%) (Table 2).

Treatment-related adverse events of grade 3 or higher that occurred in at least 10% of the patients in the daraxonrasib group were rash (in 13.7% of the patients) and stomatitis (in 12.0%). In the chemotherapy group, the treatment-related adverse events of grade 3 or higher that occurred in at least 10% of the patients were neutropenia



(in 27.6% of the patients) and anemia (in 16.4%) (Table 2).

The most common serious treatment-related adverse events that led to hospitalization were gastrointestinal events in both the daraxonrasib group (in 4.1% of the patients) and the chemotherapy group (in 5.6%). The incidence of hematologic toxic effects that led to hospitalization was higher with chemotherapy than with daraxonrasib (0% vs. 4.2% in the daraxonrasib and chemotherapy groups, respectively), as was the incidence of infections that led to hospitalization (0.4% vs. 3.3%). One patient in the daraxonrasib group died from treatment-related pneumonitis.

Treatment-related adverse events that led to

dose modifications occurred in 56.8% of the patients in the daraxonrasib group and in 71.5% of those in the chemotherapy group. Treatment-related adverse events that led to a dose reduction in at least 5% of the patients in the daraxonrasib group were rash (in 17.4% of the patients) and stomatitis (in 6.6%); in the chemotherapy group, the treatment-related adverse events that led to a dose reduction in at least 5% of the patients were neutropenia (in 16.8% of the patients), thrombocytopenia (in 13.6%), fatigue (in 12.6%), diarrhea (in 10.3%), and peripheral neuropathy (in 7.9%) (Table S3). Discontinuation of treatment owing to a treatment-related adverse event was uncommon in the daraxonrasib group as compared with the

Table 2. Adverse Events (Safety Population).*

Event	Daraxonrasib (N=241)	Chemotherapy (N=214)
	no. of patients (%)	
Any adverse event	241 (100)	209 (97.7)
Grade ≥3 event	149 (61.8)	149 (69.6)
Treatment-related adverse event	236 (97.9)	200 (93.5)
Grade ≥3 treatment-related adverse event	105 (43.6)†	123 (57.5)
Serious treatment-related adverse event	26 (10.8)	40 (18.7)
Grade 5 treatment-related adverse event	1 (0.4)	0
Treatment-related adverse event leading to dose modification	137 (56.8)	153 (71.5)
Dose interruption	135 (56.0)	118 (55.1)
Dose reduction	87 (36.1)	123 (57.5)
Treatment-related adverse event leading to treatment discontinuation	3 (1.2)‡	24 (11.2)
Treatment-related adverse event of any grade reported in ≥10% of patients; corresponding grade ≥3 treatment-related adverse event		
Rash§	206 (85.5); 33 (13.7)	12 (5.6); 0
Diarrhea	140 (58.1); 13 (5.4)	81 (37.9); 15 (7.0)
Stomatitis¶	128 (53.1); 29 (12.0)	37 (17.3); 6 (2.8)
Nausea	112 (46.5); 5 (2.1)	84 (39.3); 4 (1.9)
Vomiting	89 (36.9); 1 (0.4)	47 (22.0); 1 (0.5)
Fatigue	56 (23.2); 9 (3.7)	95 (44.4); 12 (5.6)
Anemia	44 (18.3); 10 (4.1)	85 (39.7); 35 (16.4)
Decreased appetite	41 (17.0); 3 (1.2)	48 (22.4); 1 (0.5)
Paronychia	40 (16.6); 0	0; 0
Dry skin	32 (13.3); 0	4 (1.9); 0
Aspartate aminotransferase increased	30 (12.4); 6 (2.5)	22 (10.3); 2 (0.9)
Asthenia	26 (10.8); 1 (0.4)	31 (14.5); 4 (1.9)
Neutropenia	18 (7.5); 4 (1.7)	82 (38.3); 59 (27.6)
Alanine aminotransferase increased	23 (9.5); 4 (1.7)	22 (10.3); 1 (0.5)
Edema peripheral	21 (8.7); 0	27 (12.6); 0
Thrombocytopenia**	24 (10.0); 5 (2.1)	71 (33.2); 21 (9.8)
Alopecia	8 (3.3); 0	32 (15.0); 0
Pyrexia	7 (2.9); 0	23 (10.7); 2 (0.9)
Peripheral neuropathy††	4 (1.7); 0	54 (25.2); 7 (3.3)

* All adverse events occurred after the start of treatment. The safety population included all the patients who received at least one dose of the trial treatment.

[†] Three patients (1.2%) had treatment-related adverse events of grade 4: an increased aspartate aminotransferase level in two patients and a decreased platelet count in one patient.

[‡] Two patients had a maculopapular rash of grade 3, and one patient had an increased alanine aminotransferase level of grade 3 and an increased aspartate aminotransferase level of grade 4.

§ Preferred terms include dermatitis acneiform, rash, rash maculopapular, skin ulcer, rash erythematous, eczema, dermatitis, rash pruritic, rash macular, acne, rash papular, butterfly rash, and hand dermatitis.

¶ Preferred terms include stomatitis, mucosal inflammation, aphthous ulcer, and mucosal ulceration.

|| Preferred terms include neutrophil count decreased, neutropenia, white-cell count decreased, leukopenia, and febrile neutropenia.

** Preferred terms include platelet count decreased and thrombocytopenia.

†† Preferred terms include peripheral sensory neuropathy, neuropathy peripheral, neuralgia, polyneuropathy, and peripheral motor neuropathy.

chemotherapy group (in 1.2% vs. 11.2% of the patients); two patients discontinued treatment with daraxonrasib owing to a maculopapular rash and one patient owing to elevated liver enzyme levels. Among the patients who discontinued chemotherapy owing to a treatment-related adverse event, the most common of these events was peripheral neuropathy (in 4.7% of the patients).

DISCUSSION

PDAC is one of the most challenging and lethal cancers. In the context of second-line treatment, cytotoxic chemotherapy is associated with a low incidence of response, short median progression-free survival, and a median overall survival of only 6 to 7 months.^{13,14} In this trial, in which 91.8% of the patients had RAS G12 mutations, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than the investigator's choice of chemotherapy in the RAS G12 and overall populations of patients with previously treated mPDAC, and the percentage of patients with a response was twice as high with daraxonrasib. The inclusion of multiple commonly used chemotherapy regimens in the control group reflects contemporary clinical practice.⁶ It is important to note that the results in the chemotherapy group were as expected, with outcomes consistent with those of previous clinical trials and closely aligned with historical benchmarks — findings that further underscore the magnitude of benefit observed in the daraxonrasib group.^{8,9,11}

In both the RAS G12 population and the overall population, treatment with daraxonrasib reduced the risk of death by 60%, with a median overall survival of 13.2 months among patients with previously treated mPDAC. Although cross-trial comparisons should be interpreted with caution, previous randomized mPDAC trials of first-line treatment with FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin) have shown median overall survival ranging from 8.5 to 11.1 months.³⁰⁻³³ The median overall survival observed with daraxonrasib is notable in this context, given that our trial enrolled patients who had previously received chemotherapy; however, differences in patient populations and po-

tential selection bias among patients eligible for second-line therapy should be considered.

Treatment with daraxonrasib resulted in a significantly longer time to deterioration with respect to both pain — a clinically relevant symptom in patients with mPDAC — and global health status—quality of life than chemotherapy. These patient-reported benefits complement the improvements in overall survival and progression-free survival observed with daraxonrasib.

The results of subgroup analyses of overall survival and progression-free survival are suggestive but not definitive, given the limited numbers of patients and wide confidence intervals. In prespecified subgroup analyses of overall survival, the magnitude and direction of treatment benefit with daraxonrasib were consistent across most of the clinical and molecular subgroups, including ECOG performance-status score, stage at initial diagnosis, presence of liver metastases, treatment history, and RAS mutational status. The hazard ratio estimates of progression-free survival favored daraxonrasib across most of the prespecified subgroups, with variability across smaller molecularly defined RAS subgroups. Given that less than 10% of the patients had tumors without a RAS G12 mutation, findings in this subgroup should be interpreted descriptively and in the context of the overall efficacy results in the RAS G12 and overall populations. Additional studies may be warranted to better characterize outcomes in these smaller molecular subgroups. These findings may provide clinical support for sustained inhibition of the active, GTP-bound state of RAS as a therapeutic strategy for patients with previously treated mPDAC, whereby oncogenic RAS-MAPK pathway signaling is the primary driver of tumor growth and progression.^{15-18,33}

It is important to note that the pattern of prevalence of different RAS mutations was consistent with reported patterns of prevalence in PDAC.^{15,33}

The safety profiles of daraxonrasib and chemotherapy showed no unexpected findings. The median duration of treatment was 6.2 months in the daraxonrasib group as compared with 1.5 to 3.2 months across the chemotherapy regimens. Even with a longer duration of treatment, patients in the daraxonrasib group had fewer adverse events after the start of treatment that were grade 3 or higher or that led to a dose reduction or treatment discontinuation than patients in the

chemotherapy group. The safety profile of daraxonrasib was characterized primarily by treatment-related, low-grade dermatologic and gastrointestinal adverse events; among these, events of grade 3 were uncommon, and no events of grade 4 were reported. The safety of the once-daily 300-mg dose of daraxonrasib was supported by a high relative dose intensity and a low incidence of treatment discontinuation, with adverse events managed through routine clinical interventions and dose modifications as needed (see the Supplementary Appendix for management guidelines).

Some limitations should be considered when interpreting these results. The open-label design may have influenced adverse-event reporting and treatment modifications, as well as the decision not to begin treatment after randomization; treatment was not initiated in 15.1% of the patients assigned to the chemotherapy group, in most cases owing to the patient's decision. In addition, subgroup analyses were exploratory and may have been limited by small sample sizes, particularly with respect to uncommon RAS subtypes and patients with no RAS mutation identified. Given the rarity of these subgroups in patients with PDAC, the results of those subgroup analyses should be interpreted descriptively.

In the RASolute 302 trial, once-daily treatment with oral daraxonrasib resulted in significantly longer overall survival and progression-free survival than standard cytotoxic chemotherapy among patients with previously treated mPDAC, more than 90% of whom had RAS G12 mutations. Overall survival results were largely consistent across patient subgroups, and patient-reported end points favored daraxonrasib. The results of

this trial support daraxonrasib as a clinically meaningful advance in the treatment of patients with previously treated mPDAC.

Supported by Revolution Medicines.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the participating patients, their families, and the clinicians and research staff and Akshaya Srinivasan and Asu Erden (of Nucleus Global, an Inizio Company) for medical writing support (funded by Revolution Medicines).

AUTHOR INFORMATION

Eileen M. O'Reilly, M.D.,¹ Zev A. Wainberg, M.D.,² Andrew E. Hendifar, M.D.,³ Mitesh J. Borad, M.D.,⁴ Filippo Pietrantonio, M.D.,⁵ Shubham Pant, M.D.,⁶ Pascal Hammel, M.D.,⁷ Chiara Cremolini, M.D., Ph.D.,⁸ Gulam A. Manji, M.D., Ph.D.,⁹ Paul E. Oberstein, M.D.,¹⁰ Ignacio Garrido-Laguna, M.D., Ph.D.,¹¹ Christoph Springfield, M.D., Ph.D.,¹² Nilofer S. Azad, M.D.,¹³ Makoto Ueno, M.D., Ph.D.,¹⁴ Stephen Y. Chui, M.D.,¹⁵ Ying Zhang, Ph.D.,¹⁵ Hina Patel, Pharm.D.,¹⁵ Yeonju Lee, Ph.D.,¹⁵ Zeena Salman, M.P.H.,¹⁵ and Brian M. Wolpin, M.D., M.P.H.¹⁶

¹ Memorial Sloan Kettering Cancer Center, New York; ² Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles; ³ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles; ⁴ Department of Oncology, Mayo Clinic, Phoenix, AZ; ⁵ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁶ M.D. Anderson Cancer Center, Houston; ⁷ Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Villejuif, France; ⁸ Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; ⁹ Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York; ¹⁰ Department of Hematology-Oncology, NYU Langone Health, New York University, New York; ¹¹ Huntsman Cancer Institute, University of Utah, Salt Lake City; ¹² Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany; ¹³ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; ¹⁴ Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; ¹⁵ Revolution Medicines, Redwood City, CA; ¹⁶ Hale Family Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute, Boston.

REFERENCES

1. Dbouk M, Katona BW, Brand RE, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. *J Clin Oncol* 2022;40:3257-66.
2. Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. *JAMA* 2021;326:851-62.
3. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. *CA Cancer J Clin* 2026;76(1):e70043.
4. Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. *CA Cancer J Clin* 2020;70:375-403.
5. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: pancreatic cancer (<https://seer.cancer.gov/statfacts/html/pancreas.html>).
6. Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2023;34:987-1002.
7. Hu ZI, O'Reilly EM. Therapeutic developments in pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 2024;21:7-24.
8. De La Fouchardière C, Malka D, Cropet C, et al. Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: a randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study. *J Clin Oncol* 2024;42:1055-66.
9. Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J Clin Oncol* 2016;34:3914-20.
10. Huffman BM, Basu Mallick A, Horick NK, et al. Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial. *JAMA Netw Open* 2023;6(1):e2249720.
11. Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal

- irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer* 2019;108:78-87.
12. Chiorean EG, Guthrie KA, Philip PA, et al. Randomized phase II study of PARP inhibitor ABT-888 (veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513. *Clin Cancer Res* 2021;27:6314-22.
13. Dayyani F, Macarulla T, Johnson A, Wainberg ZA. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review. *Cancer Treat Rev* 2023;113:102502.
14. Petrelli F, Parisi A, Tomasello G, et al. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. *BMC Gastroenterol* 2023;23:212.
15. Pant S, Kar S, Lin KK, Ahler E. Frequency and incidence of oncogenic RAS mutations in patients with metastatic pancreatic ductal adenocarcinoma: derived from the real-world evidence database Foundation Medicine Insights. *J Clin Oncol* 2025;43:777 (https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.777).
16. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531:47-52.
17. The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 2017;32(2):185-203.e13.
18. Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. *Cell* 2020;183:850-9.
19. Holderfield M, Lee BJ, Jiang J, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. *Nature* 2024;629:919-26.
20. Luchini C, Paolino G, Mattiolo P, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *J Exp Clin Cancer Res* 2020;39:227.
21. Varghese AM, Perry MA, Chou JF, et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. *Nat Med* 2025;31:466-77.
22. Singh H, Keller RB, Kapner KS, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. *Clin Cancer Res* 2023;29:4627-43.
23. Cregg J, Edwards AV, Chang S, et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. *J Med Chem* 2025;68:6064-83.
24. Jiang J, Jiang L, Maldonado BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. *Cancer Discov* 2024;14:994-1017.
25. Lokhandwala J, Smalley TB, Tran TH. Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. *Front Oncol* 2024;14:1394702.
26. Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. *N Engl J Med* 2026;394:1790-802.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-47.
28. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. November 27, 2017 (<https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf>).
29. Maurer W, Bretz F. Memory and other properties of multiple test procedures generated by entangled graphs. *Stat Med* 2013;32:1739-53.
30. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. *Lancet* 2023;402:1272-81.
31. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691-703.
32. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817-25.
33. Bannoura SF, Uddin MH, Nagasaka M, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. *Cancer Metastasis Rev* 2021;40:819-35.

Copyright © 2026 Massachusetts Medical Society.